

**ADMITTED EXHIBITS
SORTED BY EXHIBIT NUMBER**

	Num	Description	Date Admitted	Admitted by:	Witness
PX	1	Certified Copy of United States Patent No. 4,663,318	5/21/2007	Defendants	Levey
PX	2	Certified Copy of Patent and Trademark Office Prosecution History of U.S. Patent No. 4,663,318	5/22/2007	Plaintiffs	Davis
PX	14	Amendment After Non-Final rejection and Applicant Arguments/Remarks made in an Amendment	5/25/2007	Defendants	
PX	19	Kendall, M.J., et al., "Therapeutic Progress - Review XVIII Alzheimer's Disease," J. Clin. and Hosp. Pharm., Vol. 10 pp. 327-336 (1985).	5/22/2007	Defendants	Domino
PX	95	Memo addressed to Mr. McKnight from Dr. Davis	5/25/2007	Plaintiffs	Deposition
PX	117	A Long-Acting Cholinesterase Inhibitor Reverses Spatial Memory Deficits in Mice - Sweeney and Coyle	5/22/2007	Plaintiffs	Davis
PX	119	Letter from Gary King - ER Squibb to B. Davis RE Galanthamine Has a Narrow Therapeutic Window	5/23/2007	Plaintiffs	Davis
PX	121	Letter from B. Davis to Dr. Cozanitis RE Request to Obtain Galanthamine	5/22/2007	Plaintiffs	Davis
PX	122	Letter from Dr. Cozanitis to B. Davis RE Obtaining Galanthamine	5/22/2007	Plaintiffs	Davis
PX	123	Letter from B. Davis to St. Jordanov RE Purchase of Galanthamine	5/22/2007	Plaintiffs	Davis
PX	129	Letter from Elkan Gamzu to B. Davis RE Galanthamine Data	5/23/2007	Defendants	Davis
PX	153	Galanthamine: An Old Cholinesterase Inhibitor Revisited - Domino	5/22/2007	Plaintiffs	Domino
PX	173	Letter addressed to Bonnie Davis, M.D., from Cheryl Blume, Ph.D.,	5/23/2007	Plaintiffs	Davis
PX	213	Treatment of Alzheimer's Disease: New Outlooks for the Future - Drachman -	5/23/2007	Plaintiffs	Raskind
PX	214	Cholinergic Therapies in AD - Levey - 1999	5/21/2007	Plaintiffs	Levey
PX	272	Email from Steve Self to Barry Spencer RE Galanthamine Project Proposal	5/25/2007	Plaintiffs	Deposition
PX	295	2003 Reminyl Strategic Plan	5/22/2007	Defendants	Boghigian
PX	297a	Razadyne Marketing Contribution (YTD-Aug-06)	5/24/2007	Plaintiffs	Stewart
PX	305	License Agreement between Intelligen Corp and Ciba Geigy	5/23/2007	Plaintiffs	Davis
PX	307	Marketing Power Point Presentation	5/22/2007	Defendants	Boghigian
PX	310	Janssen Pharmaceutica, Inc. 2000-2011 Core Forecast 2001 August Update Reminyl - All Indications Spreadsheet	5/22/2007	Defendants	Boghigian
PX	311	Spreadsheets Razadyne IR Only 2001-2006 and 2001 Gross/Net Sales by Month for Razadyne/Reminyl IR Only	5/22/2007	Defendants	Boghigian
PX	312	2002 Reminyl Business Plan Summary	5/22/2007	Defendants	Boghigian
PX	314	2001 Reminyl Business Plan Summary	5/22/2007	Defendants	Boghigian
PX	315	Reminyl Sales Forecast- Scenario - 160	5/22/2007	Defendants	Boghigian
PX	323	Letter from M. Abou-Gharbia to B. Davis again regarding non-interest in her product	5/25/2007	Plaintiffs	Deposition

**ADMITTED EXHIBITS
SORTED BY EXHIBIT NUMBER**

	Num	Description	Date Admitted	Admitted by:	Witness
PX	324	Letter from B. Davis to M. Abou-Gharbia enclosing information re cholinesterase inhibitors per telephone conversation	5/25/2007	Plaintiffs	Deposition
PX	325	Letter from T. McGeehan to B. Davis responding to her 04/04/94 letter and expressing interest in use of cholinesterase inhibitors in treating Alzheimer's Disease	5/25/2007	Plaintiffs	Deposition
PX	326	Letter from T. McGeehan to B. Davis expressing interest in galanthamine	5/25/2007	Plaintiffs	Deposition
PX	327	Non-Disclosure Agreement (between Synaptech and Wyeth)	5/25/2007	Plaintiffs	Deposition
PX	329	License Agreement between Synaptech and Janssen Pharmaceutica NV	5/22/2007	Plaintiffs	Boghigian
PX	467	Letter from Douglas Watson to Intelligen RE Notice to Terminate Agreement	5/23/2007	Plaintiffs	Davis
PX	491	Letter from Robert Johnson to B. Davis RE Decline Further Interest Due to Limited Resources	5/23/2007	Defendants	Davis
PX	518	Letter from Robert Rousseau to B. Davis RE Decline Opportunity to Invest in Galanthamine	5/23/2007	Plaintiffs	Davis
PX	526	Letter from Takafumi Kitano to B. Davis RE Enclosed Confidential Documents	5/23/2007	Plaintiffs	Davis
PX	558	Letter from B. Davis to Alfred Gagne RE Enclosed Review	5/23/2007	Defendants	Davis
PX	586	Letter from Norman Pollack to B. Davis RE Committed to other Mechanistic Approaches to AD	5/23/2007	Plaintiffs	Davis
PX	595	Letter from B. Davis to William Cressman RE Enclosed Materials Relating to Galanthamine	5/23/2007	Defendants	Davis
PX	596	Letter from William Cressman to B. Davis RE Decline Opportunity	5/23/2007	Plaintiffs	Davis
PX	618	2003 Reminyl Tactical Plan	5/22/2007	Defendants	Boghigian
PX	631	Hollister, L., "Survey of Treatment Attempts in Senile Dementia of the Alzheimer Type" in C.G. Gottfries, ed., Normal Aging, Alzheimer's Disease and Senile Dementia: Aspects on Etiology, Pathogenesis, Diagnosis and Treatment, 299-306 (Editions de l'Univer	5/23/2007	Plaintiffs	Raskind
PX	632	Bartus, R., et al., "The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions," in Memory Dysfunctions: An Integration of Animal and Human Research from Preclinical and Clinical Perspectives, Annals of the New York Aca	5/21/2007	Plaintiffs	Levey
PX	633	E. Giacobini, "Cholinesterase Inhibitors Do More Than Inhibit Cholinesterase," in Becker & Giacobini, eds., Alzheimer Disease: From Molecular Biology to Thearapy, 187-204, Table III (1996).	5/22/2007	Defendants	Domino
PX	653	Bartus R. T., et al., "The Cholinergic Hypothesis of Geriatric Memory Dysfunction," Science Vol. 17 pp. 408-418 (1982).	5/21/2007	Plaintiffs	Levey

**ADMITTED EXHIBITS
SORTED BY EXHIBIT NUMBER**

	Num	Description	Date Admitted	Admitted by:	Witness
PX	654	Becker, R.E., et al., "Effects of Metrifonate on Cognitive Decline in Alzheimer Disease: A Double-Blind, Placebo-Controlled, 6-month study," Alzheimer Dis. Assoc. Disord., Vol. 12 No. 1 pp. 54-57 (1998).	5/22/2007	Defendants	Domino
PX	658	Blass, J.P. et al., "Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Two Doses of Metrifonate in Patients with Mild-to-Moderate Alzheimer's Disease: the MALT study," Alz. Dis. Assoc. Dis. J., Vol. 14	5/25/2007	Defendants	
PX	663	Coyle, J.T. et al., "Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation," Science, Vol. 219 pp. 1184-1190 (1983).	5/23/2007	Plaintiffs	Coyle
PX	670	Davis, K.L., et al., "Oral Physostigmine in Alzheimer's Disease," Psychopharmacology Bull., 19: 451-453 (1983).	5/24/2007	Defendants	Raskind
PX	680	Geerts, H., et al., "Brain Levels and Acetylcholinesterase Inhibition With Galantamine and Donepezil in Rats, Mice and Rabbits," Brain Researc., Vol. 1033 pp. 186-193 (2005).	5/23/2007	Plaintiffs	Coyle
PX	698	Mohs, R.C., et al., "Clinical Studies of the Cholinergic Deficit in Alzheimer's Disease," J. Amer. Geriatrics Soc., Vol. 33 pp.749-757, (1985).	5/24/2007	Plaintiffs	Raskind
PX	699	Mohs, R.C., et al., "Oral Physostigmine Treatment of Patients with Alzheimers Disease," Am. J. Psychiat., Vol. 142 pp. 28-33, (1985).	5/21/2007	Defendants	Levey
PX	704	Raskind, M., et al., "Galantamine in AD – A 6-month Randomized, placebo-controlled trial with a 6-month extension," Neurology, Vol. 54 pp. 2261-2268 (2000).	5/24/2007	Plaintiffs	Raskind
PX	706	Raskind, M., "The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months: A Long-term Extension Trial," Arch Neurol, Vol. 61 pp. 252-256 (2004).	5/23/2007	Plaintiffs	Coyle
PX	711	Summers, W.K., et al., "Use of THA in Treatment of Alzheimer-Like Dementia: Pilot Study in 12 Patients," Biological Psychiatry, Vol. 16, pp. 145-153 (1981).	5/21/2007	Defendants	Levey
PX	714	Swaab, D.F., and E. Fliers, "Clinical Strategies in the Treatment of Alzheimer's Disease," in Progress in Brain Research, Vol. 70 pp. 413-27 (Elsevier Science Publ. 1986).	5/23/2007	Plaintiffs	Raskind
PX	716	Wang, et al., "Progress in Studies of Huperzine A, a Natural Cholinesterase Inhibitor from Chinese Herbal Medicine," Acta Pharmacologica Sinica., Vol. 27 pp. 1-26 (2006).	5/22/2007	Defendants	Domino
PX	719	Wurtman, R.J. "Activation of Neurotransmitters in the brain: strategies in the treatment of AD/SDAT," in C.G. Gottfries, ed., Normal Aging, Alzheimer's Disease, and Senile Dementia: Aspects of Etiology, Pathogenesis, Diagnosis and Treatment, pp.275-80	5/23/2007	Plaintiffs	Coyle

**ADMITTED EXHIBITS
SORTED BY EXHIBIT NUMBER**

	Num	Description	Date Admitted	Admitted by:	Witness
PX	727	Johns, C.A., et al., "The Cholinergic Treatment Strategy in Aging and Senile Dementia," Psychopharmacology Bull., Vol. 19 No. 2 pp. 185-197 (1983).	5/21/2007	Defendants	Levey
PX	743	Daskalov, D., et. al., "Nivalin Application and Rehabilitation Treatment of Cerebral Diseases with Aphasic Syndromes," MBI Medico-Biologic Information Vol. 3 pp. 9-11 (1980).	5/21/2007	Defendants	Levey
PX	744	Luria, et.al., "Restoration of Higher Cortical Function Following Local Brain Damage," in Vincken, P.J., and Bruyn, G.W., eds., Handbook of Clinical Neurology, Vol. 3 pp. 368-433 (1969)	5/21/2007	Defendants	Levey
PX	752	Rathmann, et al. "Alzheimer's Disease Clinical features, Pathogenesis, and treatment," Drug Intelligence and Clinical Pharmacology, Vol. 18 pp. 684-91 (1984).	5/21/2007	Defendants	Levey
PX	756	Domino, E. F., "Galanthamine: Another Look at an Old Cholinesterase Inhibitor" in Giacobini, E., and Becker, R., eds., Current Research in Alzheimer Therapy. 295-303 (1988).	5/21/2007	Plaintiffs	Levey
PX	763	Davis K.L., and Mohs, R., "Enhancement of Memory Processes in Alzheimer's Disease with Multiple Dose Intravenous Physostigmine," American Journal of Psychiatry Vol. 139, No. 11, pp. 1421-1424 (1982).	5/21/2007	Defendants	Levey
PX	785	Reminyl Alzheimer's Dementia (development costs)	5/22/2007	Defendants	Boghigian
PX	792	FDA Letter regarding NDA 21-169	5/22/2007	Defendants	Boghigian
PX	793	2003 Reminyl Strategic Plan	5/22/2007	Defendants	Boghigian
PX	794	Reminyl 2000-2013 Annual Forecast-Portfolio Submission-Spring 2000	5/22/2007	Defendants	Boghigian
PX	803	Jesse David and Marion B. Stewart, "Commercial Success: Economic Principles Applied to Patent Litigation," in Gregory K. Leonard and Lauren J. Stroh, Editors, Economic Approaches to Intellectual Property Policy, Litigation, and Management, National Econom	5/24/2007	Defendants	Stewart
PX	805	Updated Exhibit 5A to Surrebuttal Expert Report of Marion B. Stewart	5/24/2007	Plaintiffs	Stewart
PX	810	Paragraph III Certification concerning U.S. Patent No. 4,663,318 and executed by Ms. Tirtho Uppal, Vice President of R&D and Regulatory Affairs for Cobalt Pharmaceuticals, Inc	5/25/2007	Plaintiffs	Paragraph III
PX	811	Declaration of Authenticity executed by Sadie Ciganek and Eon Labs, Inc.'s Paragraph III Patent Certification for U.S. Patent No. 4,663,318 executed by Steven W. Brown, R.Ph., Director of Regulatory Affairs for Eon Labs, Inc.	5/25/2007	Plaintiffs	Paragraph III
PX	812	Sandoz Inc.'s Paragraph III Certification for U.S. Patent No. 4,663,318 and executed by Camelle Lucas, Ph.D.	5/25/2007	Plaintiffs	Paragraph III
PX	818	Paragraph III certification form ANDA 77-592	5/25/2007	Plaintiffs	Paragraph III

**ADMITTED EXHIBITS
SORTED BY EXHIBIT NUMBER**

	Num	Description	Date Admitted	Admitted by:	Witness
PX	820	Paragraph III Certification for U.S. Patent No. 4,663,318	5/25/2007	Plaintiffs	Paragraph III
PX	829	Galanthamine hydrobromide versus neostigmine; DA Cozanitis (Cozanitis article with Dr. Davis's handwritten notations)	5/22/2007	Plaintiffs	Davis
PX	831	Letter from Joseph Coyle to Bonnie Davis.	5/22/2007	Plaintiffs	Davis
PX	833	Letter from Ursula Hartung to P. Dal Bianco	5/23/2007	Plaintiffs	Davis
PX	926	Record of Teleconference with FDA	5/22/2007	Plaintiffs	Boghigian
PX	932	Reminyl 2005 Brand Plan and 2005 Tactical Plan	5/22/2007	Defendants	Boghigian
PX	942	Coyle, J.T. et al., "The Effects of Different Doses of Galanthamine, A Long-Acting Acetylcholinesterase Inhibitor, on Memory in Mice"	5/23/2007	Plaintiffs	Coyle
PX	953	Special Report: "First and Only 1-year Results Reminyl vs. Aricept", Janssen Clinical Update, July 2003	5/24/2007	Plaintiffs	Stewart
PX	984	Letter from Janssen to FDA re Prior Approval Supplement for Changes to the Reminyl Package Insert; and enclosure: "Justification for Claim that Galantamine Functions as an Allosteric Potentiating Ligand (APL) on Nicotinic Receptors"	5/22/2007	Plaintiffs	Boghigian
PX	992	WAC Unit Price and Price Per Day for REM/RAZ	5/24/2007	Plaintiffs	Stewart
PX	1061	Letter from B. Davis to S. Enna (NOVA) re Enclosing Publications, Submission and Poster from Joe Coyle's Lab	5/23/2007	Plaintiffs	Davis
PX	1069	Letter from Gary A. King to B. Davis re Rejecting Licensing Opportunity for Galanthamine	5/25/2007	Plaintiffs	Deposition
PX	1122	"FDA Antidementia Drug Assessment Symposium," Department of Health and Human Services, Public Health Service, Food Drug Administration, Peripheral and Central Nervous System Drugs Advisory Panel (June 15, 1989) (transcript -- sections I and II).	5/23/2007	Plaintiffs	Raskind
PX	1148	Greenwald, Blaine S., et al. Neurotransmitter Deficits in Alzheimer's Disease: Criteria for Significance. J Am Geriatrics Society. 31: 310-316, May 1983.	5/22/2007	Defendants	Domino
PX	1156	J. Sweeney et al., "Effects of Different Doses of Galanthamine, a Long-Acting Acetylcholinesterase Inhibitor on Memory in Mice," Psychopharmacology 102: 191-200 (1990).	5/23/2007	Plaintiffs	Coyle
PX	1181	Pernov, K.G., "Nivalin and its Curative Effect upon Diseases of the Nervous System", Psychiatric Neurol Med Psychol. 13: 4316-4320, 1961.	5/21/2007	Defendants	Levey
PX	1200	Pernov, K.G., "Nivalin and its Curative Effect upon Diseases of the Nervous System", Psychiatric Neurol Med Psychol. 13: 4316-4320, 1961.	5/21/2007	Defendants	Levey
PX	1205	Thal LI, et al., "Memory Enhancement with Oral Physostigmine in Alzheimer's Disease," New England Journal of Medicine: 720 March 24, 1983.	5/21/2007	Defendants	Levey

**ADMITTED EXHIBITS
SORTED BY EXHIBIT NUMBER**

	Num	Description	Date Admitted	Admitted by:	Witness
PX	1215	Windholz, Martha et al., eds. The Merck Index [Tenth Edition]: p. 4210, 1983.	5/22/2007	Defendants	Domino
PX	1223	Flynn DD, et al., "Differential alternations in muscarinic receptor subtypes in Alzheimer's disease: Implications for cholinergic-based therapies" Life Sci. 56:869-876 (1995).	5/21/2007	Plaintiffs	Levey
PX	1228	Levey, A.I., et al., "Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer's Disease, Proc. Nat. Acad. Sci. 93:13541-13546 (1996).	5/21/2007	Plaintiffs	Levey
PX	1245	Declaration of Authenticity of Paragraph III Certification Letter, from Roxane Laboratories, Inc.	5/25/2007	Plaintiffs	Paragraph III
PX	1246	Affidavit of Authenticity of Paragraph III Certification Letter, from Ranbaxy Laboratories, Inc. (with attachments)	5/25/2007	Plaintiffs	Paragraph III
PX	1247	Stipulation Regarding Ivax (and its Paragraph III Certification)	5/25/2007	Plaintiffs	Paragraph III
PX	1248	Par Pharmaceutical, Inc.'s amendment of ANDA 77-604 withdrawing its Paragraph IV certification and converting its certification to a Paragraph III certification	5/25/2007	Plaintiffs	Paragraph III
PX	1285	Updated Exhibit 4 of the Surrebutal Report of Marion Stewart	5/24/2007	Plaintiffs	Stewart
PX	1296	Letter from L. Stockbridge (DDMAC) to V. Wagner-Weber (Janssen) responding to request for comments on proposed launch materials for Reminyl	5/23/2007	Defendants	Coyle
PX	1297	Letter from V. Wagner-Weber (Janssen) to L. Stockbridge (DDMAC) responding to comments on proposed introductory promotional materials	5/23/2007	Defendants	Coyle
PX	1308	J.E. Sweeney et al., (Abstract) Reversal of Lesion-Induced Swim Maze Deficits with a Central Acetylcholinesterase Inhibitor	5/23/2007	Plaintiffs	Coyle
PX	1321	Emr, Marian (for the National Institute of Aging). "Progress Report on Senile Dementia of the Alzheimer's Type," National Institutes of Health; Publication Vol. III (no. 86-2873, 1986).	5/23/2007	Plaintiffs	Raskind
PX	1339	Cozanitis D.A., et al., "A Comparative Study of Galanthamine Hydrobromide and Atropine/Neostigmine in Conscious Volunteers" Anaesthesist, pp. 416-421 (1971)	5/21/2007	Plaintiffs	Levey
PX	1350	Stojanov EA (1965): European Trends in Anesthesiology (O Mayerhofer, ed.) international Anesthesiology Clinics, Little, Brown & Co. Boston, Vol 3: 675-685.	5/21/2007	Plaintiffs	Levey
PX	1364	Declaration of Authenticity of Sadie Ciganek (6/27/2006) for Patent Notice (5/12/2005) for Eon Labs	5/25/2007	Plaintiffs	Paragraph III
PX	1365	Declaration of Authenticity of Brendan Magrab (6/30/2006) for Patent Notice (4/22/2005) and Paragraph III Certification (2/18/2005)	5/25/2007	Plaintiffs	Paragraph III

**ADMITTED EXHIBITS
SORTED BY EXHIBIT NUMBER**

	Num	Description	Date Admitted	Admitted by:	Witness
PX	1366	Joseph Coyle's Curriculum Vitae	5/23/2007	Plaintiffs	Coyle
PX	1369	Karen Kauffmann's Curriculum Vitae	5/23/2007	Plaintiffs	Kauffman
PX	1372	Murray Raskind's Curriculum Vitae	5/23/2007	Plaintiffs	Raskind
PX	1373	Marion Stewart's Curriculum Vitae	5/24/2007	Plaintiffs	Stewart
PX	1374	Cozanitis, "Galantamine hydrobromide versus neostigmine," Anaesthesia, 29: 163-68 (1974) (Court marked PX-1374 with the stamp for DX-58 because the articles were duplicates and both numbers were referenced in the transcript)	5/25/2007	Plaintiffs	
PX	1397	Demonstrative: "Skepticism about Galantamine 1993-1995"	5/23/2007	Plaintiffs	Davis
PX	1398	Demonstrative: "Skepticism about Galantamine 1987-1990"	5/23/2007	Plaintiffs	Davis
PX	1399	Demonstrative: "The Cholinergic Synapse"	5/23/2007	Plaintiffs	Davis
PX	1400	Demonstrative: "The Neuroendocrine Window"	5/23/2007	Plaintiffs	Davis
PX	1401	Demonstrative: "Failures of Others Pre 1986"	5/24/2007	Plaintiffs	Raskind
PX	1401a	Demonstrative: "The Search for Alzheimer's Treatment up to 2001"	Post-Trial	Defendants	Davis
PX	1402	Demonstrative: "Razadyne IR has sold over \$912.6 Million"	5/24/2007	Plaintiffs	Stewart
PX	1403	Demonstrative: "U.S. Sales of Razadyne IR have grown 18.8% per year"	5/24/2007	Plaintiffs	Stewart
PX	1404	Demonstrative: "Per-Day Prices of Razadyne, Aricept, and Exelon"	5/24/2007	Plaintiffs	Stewart
DX	58	Cozanitis, "Galantamine hydrobromide versus neostigmine," Anaesthesia, 29: 163-68 (1974) (Court marked PX-1374 with the stamp for DX-58 because the articles were duplicates and both numbers were referenced in the transcript)	5/22/2007	Defendants	Domino
DX	70	"Galanthamine Hydrobromide: A Longer Acting Anticholinesterase Drug in the Treatment of the Central Effects of Scopolamine (Hyoscine)" by D.A. Cozinitis	5/21/2007	Defendants	Levey
DX	71	"Reversal of Central Anticholinergic Syndrome by Galanthamine" by A. Baraka et al.	5/21/2007	Defendants	Levey
DX	74	Article titled "Neurology and Neurosurgery"	5/22/2007	Defendants	Domino
DX	139	P. Davies and A.J.F. Maloney Letters to the Editor of Lancet: Selective Loss of Central Cholinergic Neurons in Alzheimer's Disease	5/21/2007	Defendants	Levey
DX	167	"Correlation of Cholinergic Abnormalities with Senile Plaques and Mental Test Scores in Senile Dementia" by Perry, et al.	5/21/2007	Defendants	Levey
DX	169	"Clinical Studies with Galanthamine" by M. Rainer	5/24/2007	Defendants	Raskind
DX	318	Janssen Pharmaceutica, Inc. 2001 - 2006 core forecast capacity plan Reminyl	5/22/2007	Defendants	Boghigian
DX	345	Reminyl Forecast Summary with handwritten notes	5/22/2007	Defendants	Boghigian
DX	483	"Medical Management of Dementia" by P.A. Bhasker	5/21/2007	Defendants	Levey

**ADMITTED EXHIBITS
SORTED BY EXHIBIT NUMBER**

	Num	Description	Date Admitted	Admitted by:	Witness
DX	495	"Human Memory and the Cholinergic System" by D. Drachman et al.	5/21/2007	Defendants	Levey
DX	512	"Impact of Rivastigmine on Costs and on Time Spent in Caregiving for Families of Patients with Alzheimer's Disease" by D. Martin et al.	5/21/2007	Defendants	Levey
DX	557	"Combined Cholinergic precursor treatment and dihydroergotoxine mesylate in Alzheimer's Disease," by N. Pomara et al.	5/22/2007	Plaintiffs	Domino
DX	580	"Donepezil Reduces the Time Caregivers Spend Providing Care: Results of a One-Year, Double-Blind, Randomized Trial in Patients With Mild to Moderate Alzheimer's Disease," by V. Mastey et al.	5/21/2007	Defendants	Levey
DX	620	CV of Harry Boghigian	5/22/2007	Defendants	Boghigian
DX	625	CV Of Allan Levey, M.D., Ph.D.	5/21/2007	Defendants	Levey
DX	626	CV of Edward F. Domino	5/22/2007	Defendants	Domino
DX	627	List of Publications of Edward Domino	5/22/2007	Defendants	Domino
DX	629	Global (excluding Japan) Co-Development, Know-how and Supply Agreement for Galanthamine	5/24/2007	Defendants	Stewart
DX	650	Life Cycle Opportunity(LCO) Plan for Reminyl (galantamine)	5/22/2007	Defendants	Boghigian
DX	651	"Galanthamine for AD"	5/23/2007	Defendants	Davis
DX	652	"Oral Physostigmine in the Treatment of AD," Geriatric Medicine Today, (April 1987)	5/23/2007	Defendants	Davis
DX	655	Razadyne Label	5/23/2007	Defendants	Coyle
DX	658	Letter from Pharma Science to J. Richards (01/27/88)	5/24/2007	Defendants	Raskind
DX	1002	Demonstrative: "Reminyl is not a Commercial Success	Post-Trial	Defendants	Boghigian
DX	1021	Demonstrative: "Total Annual Prescriptions 2000-2005	Post-Trial	Defendants	Boghigian
DX	1024	Demonstrative: "Reminyl Losses"	Post-Trial	Defendants	Boghigian
DX	1107	Defendants' Demonstrative (with marginalia added by defendants' counsel)	5/24/2007	Defendants	Stewart
DX	1200	Demonstrative: "Background of Alzheimer's Disease and the Cholinergic System"	Post-Trial	Defendants	Levey
DX	1233	Demonstrative: "Background of Alzheimer's Disease and the Cholinergic System"	Post-Trial	Defendants	Levey
DX	1282	Demonstrative: "Cholinergic Treatment Approaches	Post-Trial	Defendants	Domino